Articles tagged with Prostate Cancer
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
A compound isolated from honeybee hive propolis has been found to slow the growth of prostate cancer cells and tumors in mice by shutting down their system for detecting sources of nutrition. The compound CAPE arrests early-stage prostate cancer by suppressing proteins involved in cell proliferation, offering a promising co-treatment a...
A literature review highlights the need for a tailored approach to improving quality of life in subpopulations, including African Americans, Latin Americans, Asians, and men who have sex with men. The authors emphasize the importance of considering demographic, socioeconomic, and sexual preference factors in treatment decision-making.
A new diagnostic tool using gold nanoparticles can determine the aggressiveness of prostate cancer, providing doctors with more accurate information to treat patients. The test has been validated in human tissue samples and could lead to more treatment options if clinical trials begin in two to three years.
The study found that robot-assisted radical prostatectomy (RARP) resulted in superior outcomes compared to open radical prostatectomy (ORP), including reduced need for blood transfusions and complications during or after surgery. RARP patients were also less likely to have prolonged hospital stays.
A study by Long Island University researchers found that carvacrol, an oregano constituent, induces apoptosis in prostate cancer cells. This compound may represent a promising anti-cancer agent with reduced risk of severe side effects due to its common use as food seasoning.
A study confirms that prostate cancer screening is widely ignored in men aged 75 or older, defying 2008 guidelines. Nearly half of men in this age group continue to receive screenings, highlighting the need for selective screening.
A recent study compared the adverse effects of intensity-modulated radiation therapy (IMRT), proton therapy, and conformal radiation therapy in treating localized prostate cancer. The results showed that IMRT was associated with fewer gastrointestinal adverse effects and hip fractures but more erectile dysfunction, while proton therapy...
A study published in JAMA found Intensity Modulated Radiation Therapy (IMRT) to be more effective in reducing certain side effects and preventing cancer recurrence compared to conventional conformal radiation therapy (CRT). IMRT was also comparable to proton therapy, a newer technique.
Researchers study the origins of HIV/AIDS, revealing that SIV replication in human tissues is crucial to viral efficiency. In contrast, a new study finds that autoantibodies against citrullinated proteins contribute to bone loss in rheumatoid arthritis patients.
A study shows a botanical formula significantly suppresses tumor growth in aggressive human prostate cancer cells, demonstrating its safety and effectiveness. The formula inhibits several genes related to cancer proliferation and increases the expression of cancer-fighting genes.
A new study suggests that policies to reduce healthcare costs may compromise quality care by depriving patients of needed services. The research found that regions with high rates of inappropriate imaging also had high rates of appropriate imaging, highlighting the need for a more nuanced approach.
Researchers have identified two inherited-genetic deletions in the human genome that significantly increase a man's risk of developing aggressive prostate cancer. One deletion affects a known gene, while the other is found in non-coding DNA and regulates a cascade of genes.
A new drug developed by Northwestern Medicine scientists has prevented human prostate cancer cells from spreading to other tissues. The drug inhibits movement of the cells and prevents metastasis without causing harm to normal cells or tissues.
A phase II study found metformin reduced fasting glucose, insulin levels and body mass index in men with prostate cancer. The medication also appeared to slow the growth rate of prostate cancer in a proportion of men.
A recent study has found that low oxygen levels in tumors can predict cancer recurrence in men with intermediate-risk prostate cancer. The research, led by radiation oncologists at the Princess Margaret Hospital, suggests that these patients are more likely to develop cancer recurrence within a few years of completing treatment.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
Researchers have discovered a new mechanism of prostate cancer cell metabolism by identifying the PFKFB4 gene, which is vital for tumor growth and antioxidant production. The study found that depletion of this gene in laboratory models inhibited tumor growth, suggesting potential targeted therapies.
A recent study conducted at Marshall University investigated the effects of cadmium on the prostate, revealing molecular mechanisms that induce carcinogenesis. The research, published in PLOS ONE, may lead to new therapies for prostate cancer.
Scientists at UC San Diego School of Medicine developed a new strategy for faster anticancer drug discovery by analyzing the genetic pathway of disease. They identified Peruvoside, a cardiac glycoside, as a potential treatment for prostate cancer with minimal side effects.
A new analysis suggests that circumcision before a male's first sexual intercourse may reduce the risk of developing prostate cancer. Men who were circumcised had a 15% lower risk of developing prostate cancer compared to uncircumcised men, with reduced risks for both less aggressive and more aggressive cancers.
Research at Yale University reveals that prostate cancer treatment is often not necessary for older men with short life expectancy. The study found that cancer treatment became more common among men with moderate-risk tumors and shorter life expectancies, despite being unlikely to benefit from it.
A study employing mouse models and genomic analysis of human tumors identified the Smad4 gene as a driver in bone metastasis, while 14 other genes were found to be associated with human prostate cancer prognosis. Telomerase activation confers new strengths on tumors, enabling them to progress and acquire deadly characteristics.
Four new drugs offer innovative methods of action against prostate cancer, including bone protective agents, hormone treatments and immunotherapy. These advancements could extend survival prognosis and potentially turn prostate cancer into a chronic disease.
Researchers at Thomas Jefferson University found that curcumin suppresses nuclear receptor activators, which can bypass androgen deprivation therapy. Curcumin also reduced cell number and inhibited survival in prostate cancer cells, with similar results seen in mice studies.
Researchers found a significant correlation between coronary artery disease and prostate cancer in a large study, suggesting that heart disease may be a risk factor for the malignancy. Lifestyle changes such as weight loss, exercise, and a healthy diet may help combat both conditions.
Researchers at LSU Health Sciences Center have identified a new protein called ARD1 that plays a critical role in the development and growth of prostate cancer. Inactivating this protein completely suppresses cancer growth, making it a potential target for new treatments.
A multicenter study found two biomarkers in urine to correlate with aggressive prostate cancer among men on active surveillance. The markers, PCA3 and TMPRSS2-ERG, may lead to a non-invasive test to complement biopsy for predicting disease aggressiveness and progression.
A study by UCSF researchers found that vigorous exercise is linked to increased expression of genes thought to prevent cancer progression. The study identified nearly 200 genes in healthy prostate tissue that are more active among men who exercised vigorously for at least three hours a week.
Research from the 2012 Genitourinary Cancers Symposium highlights promising new therapies for prostate cancer, including vigorous exercise and targeted drugs that improve survival rates. The studies also compare existing treatments, such as radiation therapy and hormone therapy, to determine their effectiveness.
The phase III clinical trial shows that men treated with MDV3100 had a median survival of 18.4 months compared to 13.6 months for those receiving placebo, resulting in a 37% reduction in mortality risk. This breakthrough treatment tackles drug-resistant prostate cancer, providing new hope for patients.
A new study published in Radiology found that preoperative MRI helps surgeons make informed decisions about nerve-sparing procedures for men with prostate cancer. The imaging modality changed the surgical plan in 28% of patients, without compromising oncologic outcomes.
A commonly used medication for enlarged prostates may also slow the progression of early-stage prostate cancer, according to a new study. The treatment, dutasteride, was found to delay disease progression and reduce anxiety related to the disease in patients undergoing active surveillance.
A three-year clinical trial shows dutasteride delays prostate cancer disease progression by 38% compared to placebo, while also reducing anxiety. The study suggests a viable treatment option for men with low-risk disease, offering a safer alternative to aggressive local treatment.
A Kansas State University researcher is studying foods and dietary supplements that may reduce the risk of prostate cancer. Finasteride and dutasteride drugs, which lower testosterone levels, have shown promise in reducing prostate cancer incidence but may lead to worse outcomes for those who develop the disease.
Researchers at Wayne State University are investigating the role of c-kit in bone metastasis of prostate cancer. They aim to understand how factors from the bone stimulate the production of c-kit and its ligand in prostate cancer cells, facilitating their growth and survival.
Researchers have identified a rare genetic mutation linked to a significantly higher risk of developing prostate cancer, particularly in men with a family history of early-onset disease. The mutation, called HOXB13, is associated with a 10-20 times higher risk of developing prostate cancer.
Researchers have identified a rare, inherited mutation linked to a significantly higher risk of developing prostate cancer. The mutation was found in 10-20 times more men who inherited it compared to the general population. Further studies may lead to genetic testing for inherited prostate cancer.
New research confirms that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s with underlying health conditions. The study found that six years of aggressive screening led to more diagnoses of tumors but not fewer deaths.
Men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial had no evidence of a mortality benefit from annual PSA testing compared to usual care. The study found a higher percentage of deaths from other causes among prostate cancer patients diagnosed with PSA screening, indicating over-diagnosis.
A study found that biopsy referral rates for men with high PSA levels remained stable despite recent recommendations to lower the threshold. Biopsies became slightly less common over time, likely due to growing awareness of overdiagnosis and overtreatment.
A new molecular imaging probe using ghrelin exploits the hunger hormone's unique consumption pattern by malignant prostate cancer cells. The test showed the signal was almost 5 times stronger in malignant cancer cells than in normal or benign cells.
An independent panel recommends closely monitoring men with localized, low-risk prostate cancer to delay treatment until disease progression. However, standardizing definitions and conducting additional studies are needed to clarify management strategies and optimize patient outcomes.
Researchers suggest combining PSA testing with factors like prostate size, weight, and family history to identify aggressive cancers and avoid unnecessary biopsies. This approach could potentially save up to a quarter of men from undergoing biopsies and related risks.
A study published in the Journal of Experimental Medicine reveals that protein BMP7 signals prostate tumor cells to enter a state of dormancy. Withdrawal of this protein restarts tumor growth, offering potential new therapies to prevent recurrence.
A study published in PLOS ONE found that increased consumption of ground beef or processed meat is positively associated with aggressive prostate cancer. The research team suggests that this result is due to increased levels of carcinogens in meat prepared using high heat methods, such as grilling or barbecuing.
A new mathematical model predicts individual patient responses to therapy and identifies optimal treatments for advanced prostate cancer. The model incorporates personalized data, including tumor cell characteristics, to provide more accurate treatment decisions.
Researchers have identified a genetic vulnerability in an aggressive type of prostate cancer, found in fewer than 2% of tumors but potentially treatable with targeted therapy. The study discovered that a specific drug, PHA-739358, showed dramatic responses in animal models and is now being tested in human trials.
Researchers discovered that the genes AURKA and MYCN were overexpressed in neuroendocrine prostate cancers, leading to the inhibition of tumor growth by PHA-739358. This study provides new hope for treating a highly lethal form of prostate cancer.
A study published in The Lancet shows denosumab can delay time to bone metastasis in men with castration-resistant prostate cancer. Denosumab significantly increases bone-metastasis-free survival by over four months compared to placebo, with improved outcomes also seen in delayed first bone metastasis.
A clinical trial found that denosumab treatment increases bone-metastasis-free survival by an average of four months in men with prostate cancer. The drug targets the bone microenvironment to prevent tumor spread.
Research published in BMJ Open found a significant association between contraceptive pill use and increased rates of new prostate cancer cases and deaths globally. The study suggests that environmental oestrogen exposure from oral contraceptive metabolism may contribute to this risk.
A recent study published in the Journal of Urology found that prostate cancer patients who undergo radical prostatectomy experience fewer complications and shorter hospital stays at teaching hospitals compared to non-academic institutions. The study suggests that the characteristics of teaching hospitals, including higher subspecialty ...
Combining radiotherapy with androgen deprivation therapy significantly improves overall survival for men with locally advanced prostate cancer. The study, published in The Lancet, found that patients receiving both treatments had a higher 7-year survival rate compared to those receiving ADT alone.
Researchers at Centenary Institute found prostate cancer cells have more pumps than normal, allowing them to take in leucine and outgrow normal cells. Disrupting these pumps slowed cancer growth by as much as 50%, offering hope for a treatment that slows tumor growth without surgical removal.
Research shows that repeated administrations of radionuclide therapy with 188Re-HEDP improve overall survival rates, reducing pain in prostate cancer patients with hormone-refractory bone metastases. The study found significant increases in post-treatment survival for patients receiving two or three therapies.
A study by Thordis Thorsteinsdottir found that men with prostate cancer are twice as likely to commit suicide, but a method called expressive writing can reduce this risk. Expressive writing involves getting the men affected to spend 20 minutes writing down their feelings on at least three occasions after getting their cancer diagnosis.
A low-fat diet with fish oil supplements slowed the growth of prostate cancer cells in human tissue compared to a traditional Western diet. The men on the low-fat diet also showed changes in cell membrane composition, increasing omega-3 fatty acids and decreasing omega-6 fatty acids.
Recent studies support the use of C-11 choline positron emission tomography/computerized tomography (PET/CT) scans as a staging and potentially therapeutic tool for prostate cancer. The studies found that PET/CT scans can accurately diagnose localized disease recurrence, allowing for targeted treatment options.